Novo Nordisk faces stock market bloodbath after weight-loss drug trial disappoints
Novo Nordisk, Europe’s largest company by market value, faced a stock market bloodbath on Friday after disappointing results ...
CNN on MSN1d
Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it
Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli ...
Novo Nordisk's Ozempic faces EU review for potential eye disease connection
The European Union's drug regulator said it would assess two new Danish studies that link Novo Nordisk's popular diabetes ...
Weight-loss drugmaker Novo Nordisk's shares fall on disappointing study
Shares in Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, plunged ...
Novo Nordisk's Ozempic Under Scrutiny For Potential Increased Risk Of Rare-Eye Disease
New studies link diabetes drug Ozempic to increased risk of NAION, a rare eye condition causing vision loss. Danish Medicines ...
Novo's Ozempic faces scrutiny over potential link to rare eye disease
Danish health authorities said on Monday they would ask the European Union's drug regulator to review the findings of two ...
Novo Nordisk's Ozempic Wins Approval in Europe for Chronic Kidney Disease
Novo Nordisk ( NYSE:NVO) has secured approval from the European Medicines Agency (EMA) for a kidney disease-related label ...
Health Officials Investigating Possible Link Between Ozempic and Eye-Rotting Condition
Ozempic manufacturer Novo Nordisk said patient safety is a priority and “the benefit-risk profile of semaglutide remains ...